Rheostat is a biotechnology company developing treatments for neurodegenerative disease by modulation of mitophagy and autophagy that is headquartered in Cambridge, Massachusetts and was founded in 2018 by Tim Harris, Wade Harper, Ivan Dikic and Josh Resnick.
Rheostat is focusing on molecular pathways involved in clearance of toxic components such as damaged organelles or aggregated proteins because mutations in these pathways cause many neurodegenerative diseases associated with cognitive impairment. Rheostat aims to use knowledge about these clearance pathways to find and develop small molecules that can restore cellular balance for the treatment of neurodegenerative and rare diseases.
On November 26, 2018 Rheostat Therapeutics completed their series A funding round with $23 million in funding from MRL Ventures Fund (lead investor), AbbVie Biotech Ventures, SV Health Investors, Dementia Discovery Fund, Amgen Ventures, Alexandria Venture Investments, and the Dementia Discovery Fund.
Rheostat Therapeutics raises a $23,000,000 series A round from MRL Ventures Fund and AbbVie Biotech Ventures.
Rheostat Therapeutics was founded.
Darby R. Schmidt
Senior Director, Head of Chemistry
Donato del Camino
J. Stefan Kaczmarek
President and Chief Scientific Officer
Associate Director of Biology
Documentaries, videos and podcasts
- Parkinson's diseaseA synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.
- DementiaBroad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.